Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
US-2024228562-A1 · Jul 11, 2024 · US
This page is not indexed by search engines while we improve data quality.
Pieris Pharmaceuticals Gmbh — Physics
Pieris Pharmaceuticals Gmbh holds 39 patents in Physics, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Pieris Pharmaceuticals Gmbh |
| Technology | Physics |
| Patents in slice | 39 |
| Recent patents in slice | 4 |
| First year | 2016 |
| Last year | 2024 |
Representative patents
Notable publications linking Pieris Pharmaceuticals Gmbh to Physics.
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
US-2024228562-A1 · Jul 11, 2024 · US
Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target
US-11827681-B2 · Nov 28, 2023 · US
Biomarker methods and uses
US-2023366884-A1 · Nov 16, 2023 · US
Biomarker methods and uses
US-2023366884-A1 · Nov 16, 2023 · US
Recent filings
Latest patents from Pieris Pharmaceuticals Gmbh in Physics.
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
US-2024228562-A1 · Jul 11, 2024 · US
Novel lipocalin muteins specific for connective tissue growth factor (ctgf)
US-2024228562-A1 · Jul 11, 2024 · US
Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given target
US-11827681-B2 · Nov 28, 2023 · US
Biomarker methods and uses
US-2023366884-A1 · Nov 16, 2023 · US
Biomarker methods and uses
US-2023366884-A1 · Nov 16, 2023 · US
Related pages
Navigate to parent entity pages.